Clinical Trials Browser

Active not recruiting × Carcinoma, Non-Small-Cell Lung × Docetaxel × Clear all

NCT06382129 2026-04-17

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06532032 2026-04-13

swalloWTail

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05094336 2026-03-31

MTAPESTRY 101

Phase 1/2 Active not recruiting

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT06120075 2026-03-31

ARC-27

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Phase 3 Active not recruiting

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03611738 2026-02-09

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04884282 2026-02-06

COMBI-TED

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT01933932 2025-11-19

SELECT-1

Phase 3 Active not recruiting

510 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT05132075 2025-11-10

KontRASt-02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04655976 2025-09-26

COSTAR Lung

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05020457 2025-09-26

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04721015 2025-07-03

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04140526 2025-05-23

PRESERVE-001

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT05089734 2025-05-23

EVOKE-01

Phase 3 Active not recruiting

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04685135 2025-01-22

KRYSTAL-12

Phase 3 Active not recruiting

453 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06542731 2024-08-07

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05816499 2024-06-17

AK104IIT018

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung